Clinical Trial Update: Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating a small subcutaneous glucagon dose to treat hypoglycemia in adults with type 1 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• GLUCAGON (GLUCAGON)

Snippet

Sponsor: Institut de Recherches Cliniques de Montreal | Conditions: Type 1 Diabetes | Phase 2 | Status: WITHDRAWN